The site will be unavailable from 11:00 PM GMT on Tuesday, 21 July 2026, until 4:00 AM GMT on Wednesday, 22 July 2026, due to scheduled maintenance.

Atopic dermatitis (AD) is a chronic (long-lasting) skin disease that leads to dry, itchy, and swollen red spots, which can also be painful and flare up at any time. Some people with AD have a high number of eosinophils, a type of white blood cell, which are associated with worse disease. Medicated creams and lotions, prescribed by health care providers, are meant to reduce the symptoms of AD. For some people, these creams and lotions do not work. Benralizumab injection is a medication that reduces and removes eosinophils. A clinical trial called HILLER tested benralizumab to see if there was a difference in symptoms of AD after reducing or removing eosinophils. This article explains how benralizumab reduced eosinophils and the effect it had on AD symptoms in the HILLIER study.This Plain Language Summary of Publication article (PLSP) from Immunotherapy summarises the results of a study called HILLIER. Atopic dermatitis (AD) is a long-lasting skin disease that causes the skin to become itchy, dry, and cracked. Some people with AD, who have a high number of a type of white blood cells (called eosinophils), are associated with worse disease. Creams and lotions are meant to reduce symptoms of AD, however, they don’t work for some people. The HILLIER study tested if a medication called benralizumab improved symptoms of AD after reducing or removing eosinophils.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Lack of effect of benralizumab on signs and symptoms of moderate-to-severe atopic dermatitis: Results from the phase 2 randomized, double-blind, placebo-controlled HILLIER trial’ and was published in the Journal Of The European Academy Of Dermatology & Venereology.

Visit Wiley Online Library using the link to read the article.